Evidence map›Paper›PMID 36224108›Full record

ArticleClinical genetics2023

Delineation of the clinical profile of CNOT2 haploinsufficiency and overview of the IDNADFS phenotype.

Marcello Niceta, Simone Pizzi, Francesca Inzana, Angela Peron, Somayeh Bakhtiari, Mathilde Nizon, Jonathan Levy, Cecilia Mancini, Benjamin Cogné, Francesca Clementina Radio and 12 more

Open access · hybridAbstract read
In one paragraph

Article in Clinical genetics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 12 institutions in 6 countries.

Marcello NicetaGenetics and Rare Diseases, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.ORCID 0000-0003-4766-7753
Simone PizziGenetics and Rare Diseases, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Francesca InzanaGenetic Counseling Service, Regional Hospital of Bolzano, Bolzano, Italy.
Angela PeronMedical Genetics, ASST Santi Paolo e Carlo, Ospedale San Paolo, Milan, Italy.ORCID 0000-0002-1769-6548
Somayeh BakhtiariPediatric Movement Disorders Program, Division of Pediatric Neurology, Barrow Neurological Institute, Phoenix Children's Hospital, Phoenix, Arizona, USA.
Mathilde NizonCHU Nantes, Service de Génétique Médicale, L'institut du thorax, INSERM, CNRS, UNIV Nantes, Nantes, France.
Jonathan LevyGenetics Department, AP-HP, Robert-Debré University Hospital, Paris, France.ORCID 0000-0002-8822-816X
Cecilia ManciniGenetics and Rare Diseases, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Benjamin CognéLaboratoire de Génétique Moléculaire, CHU de Nantes, Nantes, France.
Francesca Clementina RadioGenetics and Rare Diseases, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.ORCID 0000-0003-1993-8018
Emanuele AgoliniTranslational Cytogenomics Research Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.ORCID 0000-0001-6543-6225
Dario CocciadiferroTranslational Cytogenomics Research Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Antonio NovelliTranslational Cytogenomics Research Unit, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Mustafa A SalihNeurology Division, Department of Pediatrics, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Maria Paola RecalcatiMedical Cytogenetics Laboratory, Istituto Auxologico Italiano IRCCS, Cusano Milanino, Italy.
Rosangela ArancioClinica Pediatrica, Ospedale San Paolo, ASST Santi Paolo Carlo, Milan, Italy.
Marianne BesnardService de Néonatologie, Centre Hospitalier de Polynésie Française, Papeete, French Polynesia.
Anne-Claude TabetHuman Genetics and Cognitive Functions, Institut Pasteur, UMR3571 CNRS, Université de Paris, Paris, France.
Michael C KruerDepartments of Child Health, Neurology, and Cellular and Molecular Medicine, and Program in Genetics, University of Arizona College of Medicine - Phoenix, Phoenix, Arizona, USA.
Manuela PrioloUOSD Genetica Medica, Grande Ospedale Metropolitano "Bianchi-Melacrino-Morelli", Reggio Calabria, Italy.
Bruno DallapiccolaGenetics and Rare Diseases, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
Marco TartagliaGenetics and Rare Diseases, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.ORCID 0000-0001-7736-9672
Bambino Gesù Children's Hospital · ITAOL (United States) · USCentre National de la Recherche Scientifique · FRAzienda ospedaliera "Bianchi-Melacrino-Morelli" · ITBarrow Neurological Institute · USCentre Hospitalier Universitaire de Nantes · FRHôpital Robert-Debré · FRIRCCS Istituto Auxologico Italiano · ITKing Saud University · SAOspedale di Bolzano · ITUniversity of Arizona · USUniversity of French Polynesia · PF

Funding

Genomic Insights into the Neurobiology of Cerebral PalsyR01NS106298 · NINDS · UNIVERSITY OF ARIZONA · PI KRUER, MICHAEL C · 2019 to 2023
$3.7M
Genomic analysis of the Multiplex, Autozygous Populations in Cerebral Palsy (MAP CP) cohort: a focused approach to a complex diseaseR01NS127108 · NINDS · UNIVERSITY OF ARIZONA · PI Michael C Kruer · 2023 to 2026
$2.6M
NINDS NIH HHS R01 NS106298NINDS NIH HHS R01 NS127108
6 · The paper itself

Abstract

CNOT2 haploinsufficiency underlies a rare neurodevelopmental disorder named Intellectual Developmental disorder with NAsal speech, Dysmorphic Facies, and variable Skeletal anomalies (IDNADFS, OMIM 618608). The condition clinically overlaps with chromosome 12q15 deletion syndrome, suggesting a major contribution of CNOT2 haploinsufficiency to the latter. CNOT2 is a member of the CCR4-NOT complex, which is a master regulator of multiple cellular processes, including gene expression, RNA deadenylation, and protein ubiquitination. To date, less than 20 pathogenic 12q15 microdeletions encompassing CNOT2, together with a single truncating variant of the gene, and two large intragenic deletions have been reported. Due to the small number of affected subjects described so far, the clinical profile of IDNADFS has not been fully delineated. Here we report five unrelated individuals, three of which carrying de novo intragenic CNOT2 variants, one presenting with a multiexon intragenic deletion, and an additional case of 12q15 microdeletion syndrome. Finally, we assess the features of IDNADFS by reviewing published and present affected individuals and reevaluate the clinical phenotype of this neurodevelopmental disorder.

Indexed as

Intellectual DisabilityNeurodevelopmental DisordersChromosome DeletionHaploinsufficiencyHumansPhenotypeRepressor ProteinsCNOT2 protein, humanRepressor Proteins12q15_microdeletion_syndromeCNOT2_mutationsCNOTs-related disordersIDNADFS

Identifiers

PMID36224108
PMCPMC9939052
OpenAlexW4304809641

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.